Financing ·
Neurogene raises $134.8M selling 4,124,999 shares at $30 and pre-funded warrants at ~$30
NGNENeurogene Inc.
Neurogene Inc. entered into an underwriting agreement on June 30, 2026, to issue and sell 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 per warrant. Underwriters exercised their option to purchase an additional 624,999 shares. Net proceeds are expected to be approximately $134.8 million. Neurogene Inc. is a biotechnology company focused on gene therapy development.